MEDTECS INTERNATIONAL CORPORATION LIMITED
(Incorporated in Bermuda)

MONTHLY UPDATE PURSUANT TO CATALIST RULE 704(22)

---

1. INTRODUCTION

The Board of Directors (the "**Board**") of Medtecs International Corporation Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to the Company's announcements dated 3 December 2024, 27 December 2024, 17 January 2025, 24 January 2025, 27 February 2025, 27 March 2025, 25 April 2025, 8 May 2025, 28 May 2025, and 30 June 2025 (the "**Announcements**") in relation to, among others, the Winding Up Application and the Court Order in respect of Resilient Medical.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the meanings ascribed to them in the Announcements.

2. MONTHLY UPDATE PURSUANT TO CATALIST RULE 704(22)

Pursuant to Rule 704(22) of the Catalist Rules, the Board wishes to update shareholders that the creditors' meeting convened by the Liquidator of Resilient Medical on 11 July 2025 at 3:30 p.m. (Singapore time) via videoconference, in accordance with Section 148 of the Insolvency, Restructuring and Dissolution Act 2018 of Singapore ("**IRDA**"), was not held due to the absence of a quorum (which, under the IRDA, requires two members and two creditors to be present at the meeting).

As the IRDA does not provide for any adjournment in such circumstances, the Liquidator will proceed to lodge a return that (a) the creditors' meeting was duly summoned; and (b) no quorum was present at the creditor's meeting with the relevant authorities in accordance with Section 148(6) of the IRDA. Upon such lodgment, the requirement to lodge a return of the holding of the meeting under Section 148(3) of the IRDA will be deemed to have been complied with, and the Liquidator will then notify stakeholders of the intended Court application and prepare and submit the relevant documents to the Official Receiver and the Court. The liquidation will conclude upon the Court's approval and issuance of the dissolution order for Resilient Medical and for the Liquidator's release as liquidator of Resilient Medical.

The Company will provide further updates as and when there are material developments in respect of the liquidation proceedings.

3. FINANCIAL IMPACT

Based on the information currently available to it and save as disclosed in this Announcement, the Board has assessed that the winding-up of Resilient Medical and the transfer of the entire issued share capital in RMKH SG to the Company pursuant to the dividend *in specie* declared by Resilient Medical does not have a material impact on the net tangible assets per share or the earnings per share of the Company for the current financial year ending 31 December 2025. This is because the Company's outstanding receivables from Resilient Medical are approximately equivalent in value to the contributed net tangible assets of RMKH SG and its subsidiary, RMKH Cambodia (together, the "**RMKH Group**").

The Group is still awaiting the issuance of the final court order in relation to the dissolution of Resilient Medical. The financial impact assessment will be updated, if necessary, upon confirmation of the outcome of the liquidation process.

The Company will also release further announcements to update its shareholders as and when there are material developments in relation to the winding up of Resilient Medical in between the monthly updates.

4. CAUTION IN TRADING

Shareholders and potential investors of the Company are advised to read this announcement and any further announcements made by the Company carefully. Shareholders and potential investors of the Company are advised to refrain from taking any action with respect to their securities in the Company which may be prejudicial to their interests, and to exercise caution when dealing in the securities of the Company. Shareholders and potential investors of the Company should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

Submitted by Mr Clement Yang, Executive Chairman, on 25 July 2025 to the SGX-ST.

---

*This document has been prepared by the Company and its contents have been reviewed by the Company's sponsor, R & T Corporate Services Pte. Ltd. ("**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("**Exchange**").*

This document has not been examined or approved by the Exchange. The Exchange assumes no responsibility for the contents of this document including the correctness of any of the statements or opinions made or reports contained in this document.

The contact persons for the Sponsor are Ms. Evelyn Wee (Telephone Number: +65 6232 0724) and Mr. Howard Cheam Heng Haw (Telephone Number: +65 6232 0685), R & T Corporate Services Pte. Ltd., at 9 Straits View, Marina One West Tower, #06-07 Singapore 018937.